Desh Rakshak Aushdhalaya Ltd
₹ 32.8
4.99%
30 Apr
- close price
About
Incorporated in 1901, Desh Rakshak Aushdhalaya Ltd manufactures Ayurvedic and Herbal Products[1]
Key Points
- Market Cap ₹ 14.6 Cr.
- Current Price ₹ 32.8
- High / Low ₹ 34.3 / 7.65
- Stock P/E 28.0
- Book Value ₹ 21.8
- Dividend Yield 0.00 %
- ROCE 6.83 %
- ROE 4.62 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 141 days to 109 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 1.55% over past five years.
- Company has a low return on equity of 4.97% over last 3 years.
- Company has high debtors of 315 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.82 | 3.97 | 4.44 | 4.98 | 5.05 | 5.05 | 5.51 | 5.06 | 6.56 | 6.14 | 6.13 | 5.95 | 6.64 | |
| 3.58 | 3.39 | 3.79 | 4.26 | 4.39 | 4.34 | 4.73 | 4.27 | 5.61 | 4.94 | 4.74 | 4.66 | 5.32 | |
| Operating Profit | 0.24 | 0.58 | 0.65 | 0.72 | 0.66 | 0.71 | 0.78 | 0.79 | 0.95 | 1.20 | 1.39 | 1.29 | 1.32 |
| OPM % | 6.28% | 14.61% | 14.64% | 14.46% | 13.07% | 14.06% | 14.16% | 15.61% | 14.48% | 19.54% | 22.68% | 21.68% | 19.88% |
| 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | -0.05 | 0.02 | 0.02 | |
| Interest | 0.05 | 0.08 | 0.12 | 0.11 | 0.11 | 0.13 | 0.13 | 0.16 | 0.16 | 0.24 | 0.42 | 0.37 | 0.30 |
| Depreciation | 0.16 | 0.39 | 0.45 | 0.24 | 0.22 | 0.24 | 0.25 | 0.27 | 0.26 | 0.40 | 0.44 | 0.44 | 0.44 |
| Profit before tax | 0.03 | 0.12 | 0.08 | 0.38 | 0.34 | 0.35 | 0.41 | 0.37 | 0.55 | 0.57 | 0.48 | 0.50 | 0.60 |
| Tax % | 133.33% | 41.67% | 75.00% | 23.68% | 17.65% | 20.00% | 19.51% | 18.92% | 23.64% | 15.79% | 14.58% | 16.00% | |
| 0.00 | 0.07 | 0.02 | 0.29 | 0.28 | 0.28 | 0.34 | 0.30 | 0.42 | 0.48 | 0.41 | 0.43 | 0.52 | |
| EPS in Rs | 0.00 | 0.16 | 0.05 | 0.65 | 0.63 | 0.63 | 0.77 | 0.68 | 0.95 | 1.08 | 0.92 | 0.97 | 1.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | -3% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 5% |
| 3 Years: | 1% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | % |
| 3 Years: | 97% |
| 1 Year: | 350% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 |
| Reserves | 2.06 | 2.13 | 2.15 | 2.46 | 2.74 | 3.02 | 3.45 | 3.72 | 4.14 | 4.62 | 4.47 | 4.82 | 5.03 |
| 0.93 | 0.99 | 1.06 | 1.47 | 0.69 | 0.96 | 1.23 | 2.03 | 2.90 | 4.31 | 4.10 | 2.78 | 3.38 | |
| 1.65 | 1.55 | 1.71 | 1.49 | 2.07 | 2.16 | 2.01 | 1.91 | 2.87 | 2.53 | 2.51 | 4.06 | 3.59 | |
| Total Liabilities | 9.30 | 9.33 | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 16.66 |
| 3.61 | 3.61 | 3.69 | 3.75 | 3.87 | 3.93 | 4.39 | 5.38 | 6.49 | 7.82 | 8.07 | 7.68 | 7.48 | |
| CWIP | 1.35 | 1.35 | 1.35 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 |
| Investments | 0.18 | 0.18 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| 4.16 | 4.19 | 4.42 | 3.84 | 3.80 | 4.38 | 4.47 | 4.45 | 5.66 | 5.88 | 5.25 | 6.22 | 6.76 | |
| Total Assets | 9.30 | 9.33 | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 16.66 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.18 | 0.46 | 0.27 | 1.27 | 0.23 | -0.15 | -0.55 | 0.59 | 0.84 | 0.23 | 0.45 | 1.52 | |
| -0.02 | -0.33 | -0.45 | -0.66 | -0.76 | 0.04 | 0.42 | -1.27 | -1.26 | -1.95 | -0.78 | -0.09 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.74 | 0.80 | 1.35 | 0.15 | -1.34 | |
| Net Cash Flow | 0.16 | 0.13 | -0.18 | 0.61 | -0.53 | -0.04 | -0.12 | 0.06 | 0.37 | -0.36 | -0.18 | 0.09 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 191.10 | 117.68 | 127.42 | 125.33 | 146.72 | 179.25 | 196.08 | 221.45 | 214.77 | 236.00 | 216.74 | 314.70 |
| Inventory Days | 111.22 | 225.14 | 215.33 | 160.82 | 191.55 | 193.41 | 120.33 | 123.23 | 72.16 | 117.52 | 107.51 | 43.45 |
| Days Payable | 241.24 | 250.72 | 247.41 | 195.79 | 242.83 | 257.39 | 219.27 | 249.57 | 270.87 | 315.23 | 301.29 | 551.85 |
| Cash Conversion Cycle | 61.08 | 92.10 | 95.35 | 90.37 | 95.44 | 115.26 | 97.14 | 95.11 | 16.06 | 38.29 | 22.96 | -193.70 |
| Working Capital Days | 211.16 | 202.27 | 203.05 | 109.94 | 117.81 | 148.89 | 153.02 | 162.30 | 117.40 | 164.07 | 149.45 | 108.58 |
| ROCE % | 1.06% | 2.59% | 2.56% | 5.95% | 5.40% | 5.74% | 6.01% | 5.37% | 6.42% | 6.41% | 7.08% | 6.83% |
Documents
Announcements
-
Submission Of Statement Of Deviation Or Variation In Public Issue, Rights Issue, Preferential Issue Etc. For The Quarter Ended As On 31St March, 2025
2d - No deviation in use of proceeds; no public, rights, or preferential issues for Q4 FY2025.
-
Board Meeting Intimation for Pre Intimation Of The Board Meeting As Per Reg 29 Of The SEBI (LODR) Reg, 2015 And Closure Of Trading Window
28 Apr - Board meeting to approve Rs. 6 crore equity fund raise via preferential issue on May 5, 2025.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Company confirms non-applicability of SEBI Large Corporate framework for FY 2024-25; borrowings Rs. 3.09 crore.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Depositories and Participants) Regulations, 2018, we are enclosing herewith certificate issued by Registrar and Share Transfer Agent of the Company
-
Announcement under Regulation 30 (LODR)-Preferential Issue
11 Apr - Approval for raising Rs. 3 Crores and appointing internal auditor.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1][2]
DRAL is the flagship company of Bhagwant Group and one of the oldest manufacturers of Pure Ayurvedic and Herbal Products. It has a wide range of ethical medicines that are derived from herbs and form part of this holistic healthcare system. The medicines are categorized into Proprietary & Classical Medicines. The company is currently manufacturing around 450 products which are GMP certified.